AP NEWS

Global Rheumatoid Arthritis Drugs Market (2018-2022): Expected to Register a CAGR of ~8% - ResearchAndMarkets.com

December 6, 2018

DUBLIN--(BUSINESS WIRE)--Dec 6, 2018--The “Global Rheumatoid Arthritis Drugs Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering.

The rheumatoid arthritis drugs market will register a CAGR of close to 8% by 2022.

The use of biologics and biosimilars for the treatment of RA is likely to help the market grow. Unlike synthetic DMARDs, biologics have targeted mechanisms of action and serve as promising molecules for the successful treatment of RA.

Unlike conventional DMARDs, such as nonsteroidal anti-inflammatory drugs (NSAIDs) that simply provide symptomatic relief, biologics are considered a more effective medication for management of rheumatoid arthritis.

Social stigma associated with RA mainly due to physical deformities and functional limitations in RA patients. Various strategies are being adopted to tackle social stigma at the patient level.

Market Trends

High cost of RA drugs Use of biologics/biosimilars for treatment of RA Use of gene therapy for RA treatment Market dominance by TNF-alpha inhibitors Need for rheumatologists

Key Players

AbbVie Amgen Johnson & Johnson Novartis Pfizer UCB Pharma

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

Market ecosystem Market characteristics Market segmentation analysis

PART 05: PIPELINE ANALYSIS

Pipeline analysis

PART 06: MARKET SIZING

Market definition Market sizing 2017 Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS

Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition

PART 08: MARKET SEGMENTATION BY TYPE OF MOLECULE

Segmentation by type of molecule Comparison by type of molecule Biologics - Market size and forecast 2017-2022 Small molecules - Market size and forecast 2017-2022 Market opportunity by type of molecule

PART 09: MARKET SEGMENTATION BY TYPE OF RA

Segmentation by type of RA Seropositive RA Seronegative RA

PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE

Geographical segmentation Regional comparison Americas - Market size and forecast 2017-2022 EMEA - Market size and forecast 2017-2022 APAC - Market size and forecast 2017-2022 Market opportunity

PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES

Market drivers Market challenges

PART 14: MARKET TRENDS

High cost of RA drugs Use of biologics/biosimilars for treatment of RA Use of gene therapy for RA treatment Market dominance by TNF-alpha inhibitors Need for rheumatologists

PART 15: VENDOR LANDSCAPE

Overview Landscape disruption

PART 16: VENDOR ANALYSIS

Vendors covered Vendor classification Market positioning of vendors AbbVie Amgen Johnson & Johnson Novartis Pfizer UCB Pharma

For more information about this report visit https://www.researchandmarkets.com/research/bk8l6p/global_rheumatoid?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181206005826/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Immune Disorders Drugs,Musculoskeletal Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 12/06/2018 01:44 PM/DISC: 12/06/2018 01:44 PM

http://www.businesswire.com/news/home/20181206005826/en

AP RADIO
Update hourly